O. Hamid, “Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis”, J of Skin, vol. 7, no. 2, p. s179, Mar. 2023.